

SIGA

Company Overview

A Leader in Global Health
& Infectious Diseases

September 2024



Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. (“SIGA”) products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.


For a more detailed discussion of our risks, see the Risk Factors section in SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.



Contents

- 1 **Introduction**
- 2 **Era of Emerging Viruses**
- 3 **TPOXX[®]**
- 4 **Growth Strategy**
- 5 **Financial Summary**


SIGA at a Glance



Stellar Revenue Generation
>\$1bn of Procurement Contracts
from 10+ years Working with
Governments



TPOXX
A Foundational Franchise &
Trusted Treatment for
Smallpox & Mpox⁽²⁾




Strong Expertise
Infectious Disease, Public
Health, and Government
Contracting



25+ Countries
Where Products
Are Sold

Revenues by Geography⁽¹⁾



SIGA is a public, commercial-stage pharmaceutical company focused on providing **solutions** for **unmet needs** in emerging **infectious diseases**. The company is headquartered in New York City, with research and development operations in Corvallis, Oregon.

(1) From 2020 - 2023
(2) Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX is not approved as a treatment for mpox in the U.S.

SIGA is a Leader in Global Health and Infectious Disease

Fully Integrated Infectious Disease Capabilities

Highly profitable, commercial stage pharmaceutical company operating within infectious disease and health security

Experienced senior management team with **deep expertise in commercial, antiviral R&D, and government contracting & relations**

Fully integrated, **U.S.-based operational supply chain**

Leading TPOXX Product Platform

Lead product is oral TPOXX, an antiviral drug for treating smallpox (FDA approved in 2018) and orthopox (EMA approved in 2022)

Only **one of two approved antivirals for orthopox treatment**; distinct mechanism of action supports strong efficacy and safety profile

Track record of securing multi-year government awards across multiple agencies

Foundation for Continued Attractive Growth

Near term opportunities for TPOXX indication expansions (mpox in the U.S., post-exposure prophylaxis "PEP", pediatric formulation)

Geographic expansion ex-U.S., including Canada, Europe, ROW

Able to leverage antiviral and strong government procurement capabilities to move into complementary therapeutic areas with similar points of patient care

Attractive inorganic growth opportunities to expand into adjacencies and therapeutic areas with scientific and commercial synergies


Best-in-Class Financial Performance

Realized **~\$500 mm of TPOXX revenue with robust gross margins** in 2020 - 2023

Highly profitable company with **~\$300 mm in pre-tax operating income** in 2020 - 2023

Robust balance sheet and cash flow with **minimal CAPEX and no debt**

Executing on our Strategy for Growth




Comprehensive Capabilities Provide Strong Foundation



Entrenched relationships with key government agencies

Positive track-record of contract performance



Proven R&D capabilities

Close coordination with government agencies to jointly develop high-impact therapies

Ongoing label expansions for TPOXX



Fully integrated U.S. end-to-end supply chain network

Experienced Leadership in Infectious Diseases and Government Relations



Diem Nguyen, PhD, MBA
Chief Executive Officer

Visionary: Spearheaded \$11 bn revenue global operating units that generated one third of Pfizer's annual profit




Dan Luckshire
Chief Financial Officer

Operational Excellence and Financial Integrity Leader: Demonstrated leadership in finance, investment banking, and commercial operations



Dennis Hruby
Chief Scientific Officer

World Renowned Infectious Disease Researcher: Led the discovery, development, and approval of TPOXX



Larry Miller
General Counsel

Strategic Partner: Experienced lawyer with breadth of capabilities in corporate law, M&A, and public companies



Tove Bolken
SVP, Operations and Chief Supply Chain Officer

Flawless Operator: Managed manufacturing, process development and supply chain oversight




Persistent, Durable Financial Performance Over Time


Revenues (\$mm)




Pre-tax Operating Income (\$mm)



Capital Management⁽¹⁾ (\$mm)



Averages for 2020 - 2023 (\$mm)




(1) Includes dividends and share repurchases



Era of Emerging Viruses

Emergence of New Viruses Threaten Health Security



Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare



11:37
Safari
Covid-19 Guidance > Symptoms and Treatment JN.1 Variant Ne

NEWS ANALYSIS

New Infectious Threats Are Coming. The U.S. Probably Won't Contain Them.

The coronavirus revealed flaws in the nation's pandemic plans. The spread of monkeypox shows that the problems remain deeply entrenched.


11:35
Post
Siga Technologies @SigaTech Follow

"Somebody would reconstruct, say, a smallpox virus and have that spread, and that would not only kill millions, it could potentially kill billions"
- Bill Gates on bioterrorism, 2017, PBS



Smallpox Remains a Significant Threat Today

Highly contagious and fatal disease in susceptible population



Global Outbreak Demonstrated the Need for Orthopox Antiviral Therapies to Help Mitigate Ongoing Threats

2022 Mpox Outbreak

Mpox belongs to orthopox family

Lesions are extremely painful with weeks to months of recovery

In 2022, global mpox outbreak impacted >90,000 cases

Case fatality >160 deaths

Rapid Containment Response

TPOXX quickly identified as a potentially effective treatment

In the U.S., the CDC distributed 80,000+ bottles of oral TPOXX and 13,000+ vials of IV TPOXX under EAU

Multiple clinical trials initiated to evaluate TPOXX as a potential treatment for mpox

Ongoing Threat

CDC and WHO concerned mpox⁽¹⁾ is a forewarning of graver threats

Ongoing outbreak in the DRC with 22,000+ cases and 1,200 deaths since January 2023

Caused by Clade 1 with case-fatality far greater than the 2022 strain (~5-10%)

CDC issued a health alert in December 2023

WHO declared a public health emergency of international concern in August 2024

FDA, NIH and CDC have been Working to Support the Expanded Access Use of TPOXX

(1) TPOXX is approved to treat mpox in the EU and UK.



TPOXX: A Differentiated Product

Orthopox Family Encompasses a Spectrum of Diverse Diseases

Orthopoxvirus infections can cause a range of febrile rash illnesses in humans, from fairly benign, localized skin infections to severe systemic infections. There are four orthopoxvirus species known to cause human disease:

VARIOLA VIRUS (SMALLPOX)

Causative agent of smallpox; TPOXX received FDA approval for treatment in 2018.

MPOX VIRUS

Mpox virus causes intermittent human infections, primarily in Central and West Africa, although isolated outbreaks have been identified in the United States and Sudan; the disease is very similar to smallpox. Case fatality rates range from <1% to >10% depending on virus clade.


COWPOX VIRUS

Human cowpox virus infection is classically associated with occupational exposure to cattle; however, other animals, including rats, pet cats, and zoo and circus elephants, have been implicated. Infection can be lethal in immunocompromised individuals.

VACCINIA VIRUS

Vaccinia virus is used as the smallpox vaccine and some cancer therapies in development. It causes sporadic disease in those immunized/treated, contacts of those immunized/treated, and laboratory workers. Infection can be lethal in immunocompromised individuals.

TPOXX is a Clinically Differentiated Medical Countermeasure





TPOXX Demonstrates Strong Safety and Efficacy in Humans

Note: TPOXX/Tecovirimat SIGA approved by the U.S., Canada, EU, and UK; TEMBEXA approved by the U.S. and Canada; ACAM2000 approved by the U.S., Australia, and Singapore; and MVA-BN approved by the U.S., Canada, and EU.



Demonstrated Track-Record of >\$1B Successful Long-Standing Government Contracts for TPOXX

	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
PROCUREMENT DURATION	2011-2018	2018-current
KEY AGENCY INVOLVED	U.S. Biomedical Advanced Research and Dev. Authority ("BARDA") 	U.S. Biomedical Advanced Research and Dev. Authority ("BARDA") 
CONTRACT VALUE	<ul style="list-style-type: none"> ▪ \$461 mm total procurement contract value ▪ \$461 mm fully delivered 	<ul style="list-style-type: none"> ▪ \$546 mm total procurement contract value ▪ \$520 mm ordered; \$341 mm delivered as of 12/31/2023; \$26 mm outstanding options

New Contract with Administration for Strategic Preparedness & Response (ASPR) for U.S. National Stockpile Targeted in 2024





Growth Strategy

Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications

TPOXX Franchise is the Foundation for Expansion with over \$1bn in Multi-Year Contracts

PEP Program

(post-exposure prophylaxis)

Addresses **time gap** between exposure and signs of clinical infection

Studies are supportive of the use of TPOXX in PEP to **reduce morbidity and mortality**

Targeting FDA **submission** in 2025

Mpox Program

Critical to provide in countries where not approved for this virus

Supporting 4 ongoing randomized controlled **trials** (RCT) and multiple observational studies

PALM 007 topline results reported in Aug. 2024; working with NIAID, the trial sponsor, to analyze the data

Working with government sponsors and FDA on **pathway to submission**

Pediatric Program


Important program to protect the **pediatric population**

Completed trial that demonstrates **equivalence of drug exposure** in volunteers (oral vs liquid formulation)

Designing **clinical program** to support regulatory filing


Selected a **manufacturer** to prepare clinical supplies

TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox



PEP program has received \$27 mm of development funding from U.S. Department of Defense

TPOXX (tecovirimat) Clinical Trials for Mpox



TPOXX (tecovirimat) Clinical Results in Mpox

The top line data from the **PALM 007 study** conducted in the DRC was reported in August 2024. While tecovirimat did not reach statistical significance on its primary endpoint of being superior to placebo in lesion resolution for all patients, we believe it showed encouraging results in important groups of patients.

EFFECTIVE



Tecovirimat provided clinical benefits

- Severe disease (>100 lesions)
- 1-7 days after onset of mpox-related symptoms

Potential benefits for those living with HIV or other immune-suppressing conditions is currently being studied in STOMP & UNITY trials*. This data is also being collected by CDC in real-world scenarios

SAFE



Favorable safety profile

- Safety profile similar to placebo in healthy volunteers
- No study drug-related AEs or SAEs observed in mpox trial of ~600 patients
- Worldwide experience in ~8,000 patients, confirms no safety signals

*Individuals living with severe HIV as defined in study protocols are receiving open label tecovirimat

Cultivate Partnerships to Expand Global Access

Collaborating with Governments and Other Partners on Health Security is Best-in-Class Core Competency

Strong Long-Standing Partnerships

- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Biomedical Advanced Research and Development Authority (BARDA)
- Stockpiling Lifesaving Medical Countermeasures
- U.S. Department of Defense



Proven Track Record

- Secured funding for over \$1 bn in multi-year contracts for TPOXX
- Sold +\$100 mm of TPOXX to more than 25 countries since 2020

Common Goal of Global Health Security

- Shared understanding that with the current geopolitical environment, the risk of a rogue actor or nation weaponizing a virus has increased
- Clear recognition of the need to stockpile TPOXX and other critical medicines in the event of an outbreak to quickly contain the impact



Financial Summary

Strong Financial Performance

1 U.S. Government Orders under Current Contracts

- ~\$400 mm of TPOXX (1.2 mm courses) ordered for SNS over the past 4 years
- ~\$11 mm of oral TPOXX ordered by the Department of Defense in 2023

2 International Orders

- Over \$100 mm of international oral TPOXX ordered by more than 25 countries since 2020


3 Financial Results

- Cumulative pre-tax operating income of ~\$300 mm for the 2020 - 2023 time period
- 2023 product sales of \$131 mm and pre-tax operating income of \$84 mm

(\$ in millions)

	FY 2020	FY 2021	FY 2022	FY 2023
Product Sales				
Oral TPOXX (U.S. Government)	\$113	\$113	\$7	\$110
Oral TPOXX (International)	\$2	\$13	\$71	\$21
IV TPOXX	---	---	\$7	---
Total Product Sales	\$115	\$127	\$87	\$131
Pre-Tax Operating Income	\$85	\$89	\$43	\$84
Net Income	\$56	\$69	\$34	\$68

Key Takeaways



We are Well Positioned for Growth and Attractive Returns Over Time